containing 50 % shells and 50% seeds (by weight) and the other version containing 70% of shells and 30% of seeds (by weight). All animals 16 dogs and 16 horses were treated for a time period of three month, the dose was 0.3 g pr kg daily, and data was lumped together. The human studies also tested two different versions of the same shell and seed containing Rose-hip remedy: The daily dose of one version was 1.2 g seeds and a similar amount of shells (A version) and the daily dose of the version (B) was 0.2 g seeds combined with 1.8 g shells. The human study was performed in two groups of middle aged patients with modest osteoarthritis. A seasonal variation is reported for CRP (higher during winter), and both groups started treatment late autumn. A number of 43 patients were given high dose seed version and 40 other patients were given corresponding placebo. Another group of 32 patients (B group) were given the low seed version and corresponded to 30 patients on placebo. Data given are mean +/-SD. Wilcoxon test for matched pairs was used within groups and Mann-Whitney when comparing placebo and active treatment. A p level less than 0.050 was regarded as statistically significant. Results: Treatment with the high seed level resulted in a statistically significant reduction in chemotaxis from 28.6 +/-13.5 to 5.6 +/-3.4 in a group of eight animals (p<0.010). A modest and insignificant increase was observed in a placebo group of identical magnitude, p <0.050 comparing the two groups. The low dose seed preparation, when tested in another eight animals resulted in an insignificant 3% increase of chemotaxis (p<0.830). No change in chemotaxis was observed in the placebo group and there were no significant difference between groups. Patients reaction to the high seed and low seed preparation supported the observations from animal studies. Treated with the A version (1.2 g seeds daily) resulted in a insignificant CRP reduction from 2.07 +/-2.19 to 1.68 +/-1.28 mg/l, a reduction of 18%. In the placebo group CRP levels increased statistically significant from 1,43 +/-0.91 to 1.89 +/-1.35 mg/l (p<0.014) an increase which is most likely due to reported seasonal variation. The two groups were significantly different from each other as indicated by a Mann-Whitney p value of 0.042. In the B group receiving low dose seed treatment (0.2 g daily) there was a modest and insignificant increase of 20% in CRP levels, which was not significantly different when compared to observations from the corresponding placebo group (p<0.339).
Conclusion:
The present data suggest that Rose-hip seeds are of importance to keep the optimal anti-inflammatory profile in Rose-hip preparations. Purpose: Osteoarthritis (OA) is a degenerative joint disease in which articular cartilage matrix is no longer in homeostatic balance, resulting in a net loss of chondroitin sulfate (CS)-rich glycosaminoglycans (GAGs). The pro-inflammatory environment of synovial fluid has been shown to result in an increase in hyaluronic acid (HA) turnover. Consequently the turnover of CS and HA are considered key parameters to evaluate the degree and evolution of OA. We conducted a double blind randomized clinical trial to determine if there would be changes in turnover of CS and HA in the synovial fluid (SF) of knee OA patients treated with a patented hyaluronic acid formulation for oral use (Oralvisc Ò ) as compared to placebo. Methods: 51 symptomatic knee OA patients were recruited sequentially at the time of an outpatient visit for OA. Subjects were between the ages of 50-75 years, had knee effusion, and a pain visual analog score (VAS) >50mm. 40 patients completed the study, 21 had been randomly selected to receive 80 mg daily of Oralvisc Ò , and the remaining 19 had identical appearing placebos. Each month they were evaluated for VAS and WOMAC pain and joint function. A subset of 10 subjects per treatment group began a 2-day long oral administration of heavy water (35 mL 2 H 2 O TID for 2 days) at the conclusion of the treatment phase (Week 12), followed by a synovial fluid aspiration in the affected knee. Synovial fluid lavage samples were analyzed for 2 H-labeling of component GAGs by gas chromatography/ mass spectrometry (GC/MS) to obtain fractional synthesis rates of HA and CS in SF.
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Results:
The age, sex, race, BMI, KL scores, as well as VAS pain and WOMAC function were balanced between groups at the beginning of the trial. Treatment with oral HA during 3 months resulted in a significant improvement in VAS pain (p¼0.0035), WOMAC pain (p¼0.0259) and WOMAC function (p¼0.0132) compared to placebo. The stableisotope-mass spectrometry method was successfully implemented for the clinical study of SF GAG kinetics. The rate of HA turnover was 0.78AE0.42 / day (i.e., 78% per day) in placebo-treated OA patients (n¼10; Fig. 1 ). With 12 weeks of oral HA treatment, the mean rate of HA turnover declined by 45% to 0.42AE0.24 / day (p ¼ 0.046). While we have not directly compared the rate of HA turnover in normal vs. osteoarthritic knees, comparison of the current results with data from a previous study in ACL patients suggests that these osteoarthritis patients (0.78 / d) have elevated HA turnover relative to "normal" subjects (0.25 / d), and that oral HA partially normalized the HA turnover rate. CS molecules in the SF were also highly enriched, with the majority of the patients recording the maximum measureable turnover rate for this assay (>140% / day). Thus, virtually all of the SF-derived CS was recently synthesized, suggesting a defect in the retention of potential repair molecules in osteoarthritic cartilage. Conclusions: This is the first study of its kind to show that the use of an oral HA (Oralvisc Ò ) agent in knee OA patients can lead to a significant impact on HA turnover in synovial fluid. The normalization in HA turnover was paralleled by an overall decrease in pain scores and improvement in joint function. Further studies are needed to investigate its mechanism but this novel form of oral HA may provide a safe alternative treatment to correct the homeostatic imbalances in the progression of OA. Purpose: Broccoli is rich in glucoraphanin (a glucosinolate). When broccoli is cut or chewed, glucoraphanin is converted by an enzyme, myrosinase, to sulforaphane (an isothiocyanate). Similar compounds are derived from other cruciferous vegetables and these compounds are therefore accessible via the diet. Sulforaphane (SFN) has been reported to regulate signalling pathways relevant to chronic diseases. Our study investigated whether sulforaphane can abrogate cartilage destruction in osteoarthritis and examined mechanism of action in chondrocytes. Methods: The bovine nasal cartilage explant model (BNC) and destabilisation of medial meniscus (DMM) murine model of osteoarthritis were used to study chondroprotection by SFN. Histone acetylation, gene expression, transcription factors nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and nuclear factor kappaB (NF-kB) signalling were examined.
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